Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells.

Elevated cellular sorbitol levels resulting from conversion of increased glucose by aldose reductase might deplete cellular myoinositol content, which could then lower inositol phosphates (InsPs) and diacylglycerol levels, key regulators of protein kinase C (PKC). Secondary to altered PKC activity, other cellular enzymes such as (Na,K)-ATPase could be affected. To test this hypothesis we examined the association between PKC activity, (Na,K)-ATPase activity, and sorbitol, myoinositol, and InsP levels in cultured bovine retinal capillary endothelial cells, a cell type prominently involved in diabetic retinopathy. Elevating glucose concentration in culture media from 100 to 400 mg/dl led to a 100% increase in sorbitol levels, which could be inhibited completely by sorbinil, an aldose reductase inhibitor. In contrast, no changes were observed in myoinositol or InsP levels. Subfractionated PKC activities showed a 100% increase in the membranous pool with a parallel decrease in the cytosolic fraction. Adding sorbinil did not affect PKC activity, whereas the PKC agonist, phorbol myristate acetate (PMA), stimulated translocation of PKC. Ouabain-inhibitable (Na,K)-ATPase activity was decreased 70% by elevated glucose levels. This decrease could be prevented by adding either PMA or sorbinil. Thus, in retinal capillary endothelial cells elevated glucose concentration can affect PKC and (Na,K)-ATPase activities, probably via different mechanisms.

Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries.

Antisense experiments are often complicated by the lack of reliable methods for selecting effective antisense sequences. Chimeric oligodeoxynucleotide (ODN) libraries and ribonuclease H (RNase H) were used to identify regions on the 1253 nucleotide angiotensin type-1 receptor (AT1) mRNA that are accessible to hybridization with antisense ODNs. Phosphorothioate antisense ODNs targeted against accessible sites reduced AT1 receptor levels by at least 50% in cell culture. ODNs to 4 sites produced a 70% to 80% reduction. In contrast, most sequences targeted between accessible sites were ineffective. When injected into the brains of rats, ODNs targeted to accessible sites reduced AT1 (by 65%) but not AT2 receptor levels. Additionally, AT1 receptor function as measured by agonist-induced water intake, was significantly attenuated in these rats. ODNs directed between accessible sites were ineffective at suppressing water intake. RNA mapping can be applied to any RNA target to facilitate selection of multiple, active antisense sequences for cell culture and in vivo experiments.

Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors.

In bovine adrenal medullary cells synergistically acting type 1 and type 2 angiotensin II (AII) receptors activate the fibroblast growth factor-2 (FGF-2) gene through a unique AII-responsive promoter element. Both the type 1 and type 2 AII receptors and the downstream cyclic adenosine 1',3'-monophosphate- and protein kinase C-dependent signaling pathways activate the FGF-2 promoter through a novel signal-transducing mechanism. This mechanism, which we have named integrative nuclear FGF receptor-1 signaling, involves the nuclear translocation of FGF receptor-1 and its subsequent transactivation of the AII-responsive element in the FGF-2 promoter.

Emerging mechanisms of the behavioral effects of steroids.

Within two models of steroid-modulated behavior, sodium appetite and sexual receptivity, novel mechanisms of steroid action have emerged. These include interactions between different types of steroid receptors, plasticity of synapses, activation of unliganded steroid receptors, and rapid effects or steroids. These mechanisms highlight the diversity of steroid action in the central nervous system.

Functional interactions between neuronal AT1 and AT2 receptors.

Angiotensin II (Ang II), via the activation of the AT1 and AT2 receptors regulates electrophysiological responses of catecholaminergic neurons. This study was designed to determine if functional interactions between AT1 and AT2 receptors exist in a single neuron. Ang II caused two unique electrophysiological responses characteristic of receptor crosstalk. First, Ang II elicited an AT1 receptor-mediated decrease in I(K) followed by an AT2 receptor-mediated increase in I(K). Second, Ang II elicited an AT2 receptor-mediated increase in I(K) followed by an AT1 receptor-mediated decrease in I(K). AT1 and AT2 receptors were co-localized on the catecholaminergic neurons. These observations suggest, for the first time, the existence of a crosstalk between Ang II receptor subtypes that may be significant in the physiological activity of catecholaminergic neurons.

Glucocorticoid and mineralocorticoid regulation of angiotensin II type 1 receptor binding and inositol triphosphate formation in WB cells.

Mineralocorticoids, glucocorticoids, and angiotensin II (AngII) act cooperatively to maintain body fluid homeostasis. Mineralocorticoids, such as aldosterone and deoxycorticosterone-acetate (DOCA), function synergistically with AngII in the brain to increase salt appetite and blood pressure. In addition, glucocorticoids increase AngII-induced drinking and pressor responses and may also facilitate the actions of aldosterone on salt appetite. The AngII Type 1 (AT1) receptor mediates many of the physiological and behavioral actions of AngII. This receptor is coupled to the G-protein Gq, which mediates AngII-induced inositol triphosphate (IP3) formation. The WB cell line, a liver epithelial cell line that expresses the AT1 receptor, was used to examine the cellular basis of glucocorticoid and mineralocorticoid regulation of AT1 function. In this study corticosterone and dexamethasone treatments increased the number of AT1 receptors by activating the glucocorticoid receptor (GR). This increase in AT1 binding resulted in enhanced AngII-stimulated IP3 formation. However, only supraphysiological doses of aldosterone or DOCA increased AT1 binding, and this effect also was mediated by GR activation. Furthermore, despite evidence that mineralocorticoids and glucocorticoids function together to increase AngII-stimulated actions in vivo, aldosterone and dexamethasone did not act synergistically to affect AT1 binding, Gq expression, or IP3 formation. These results indicate that GR activation, and the subsequent increases in AT1 binding and in AngII-stimulated IP3 formation, may represent a cellular mechanism underlying the synergy between adrenal steroids and AngII.

Role of the amino terminus in ligand binding for the angiotensin II type 2 receptor.

Key amino terminal residues in type 1 (AT1) angiotensin II (AngII) receptors are not conserved within type 2 (AT2) receptors. We therefore characterized amino terminal mutants that are transiently expressed in COS-3 membranes. AT2 amino terminal deletion drastically reduced affinity for AngII, suggesting its importance for this subtype. AT1-AT2 amino terminal exchanges retained wild type AngII affinities (Kd ranging from 3-5 nM), indicating compensation despite substantial sequence dissimilarities. Finally, binding of AT2 selective ligands (CGP42112A and PD123319) was not dependent on the amino terminus.

Mutation of a conserved fifth transmembrane domain lysine residue (Lys215) attenuates ligand binding in the angiotensin II type 2 receptor.

A fifth transmembrane domain lysine residue is conserved in both the type 1 (AT1) and type 2 (AT2) angiotensin II (AngII) receptors. This lysine (Lys199) is believed to play a critical role in peptide binding for the AT1 receptor. To evaluate its possible role in the AT2 receptor, the analogous AT2 residue (Lys199) was changed to glutamine. This mutation greatly reduced the affinity for both 125I-AngII and 125I-Sar1,Ile8-AngII and abolished binding to the non-peptide 125I-PD122979. These data indicate that despite a relatively low homology of 34%, some commonalities in the binding mechanism for AngII may exist between the two subtypes.

Cloning and expression of angiotensin II type 2 (AT2) receptors from murine neuroblastoma N1E-115 cells: evidence for AT2 receptor heterogeneity.

Homology-based PCR was used to isolate angiotensin II type 2 (AT2) receptor cDNA from murine neuroblastoma N1E-115 cells. Despite subtle differences in the nucleotide sequence (the N1E-115 clone coded for Phe133 as TTC and Gln326 as CAG; base substitutions are in bold-italics), the AT2 receptor protein was identical to other reported murine AT2 clones. When transfected into COS-1 cells, the expressed AT2 receptor displayed high affinity for AngII and for AT2-selective compounds, GTP gamma S-insensitive agonist binding and enhanced agonist binding by dithiothreitol. Previously, we have demonstrated that N1E-115 cells possess two distinct subpopulations of AT2 receptors, defined as peak I and peak III receptors, that can be separated by heparin-sepharose chromatography. The two subpopulations differ pharmacologically, biochemically and immunologically. The binding properties of the cloned AT2 receptor closely resembled that of peak III receptors. Moreover, antisera raised against peak I AT2 receptors failed to immunoreact to either peak III receptors or cloned AT2 receptors expressed in COS-1 cells. Collectively, these data suggest that the cloned AT2 receptor is identical to peak III receptors from N1E-115 cells and that a novel AT2 receptor (peak I) remains to be cloned.

Sodium appetite elicited by intracerebroventricular infusion of angiotensin II in the rat: I. Relation to urinary sodium excretion.

Intracerebroventricular infusion of angiotensin II (Ang II) elicits a substantial sodium appetite in the rat. The present results demonstrate that this phenomenon consists of a small, early phase of sodium ingestion that is not the result of prior sodium loss but that thereafter urinary excretion of sodium exceeds intake and consequently the animals become hyponatremic and hypovolemic. The larger and more sustained bouts of sodium ingestion occurring 8-12 hr after the start of the Ang II infusion appear to represent a behavioral compensation for this incurred sodium deficit. These results confirm the arousal of a sodium appetite by action of Ang II on the brain but indicate the need for caution in assigning to it a direct and exclusive role in the neuroendocrine control of sodium intake.

Sodium appetite elicited by intracerebroventricular infusion of angiotensin II in the rat: II. Synergistic interaction with systemic mineralocorticoids.

Angiotensin and mineralocorticoids, the hormones of sodium conservation, acted together to arouse a sodium appetite with shorter latency and greater magnitude than is produced by larger amounts of each acting alone. This potentiation was selective for sodium ingestion and occurred in the absence of significant changes in sodium balance. Therefore, because endogenous angiotensin and mineralocorticoids are concurrently elevated during sodium deficiency, sodium appetite may be aroused by a synergy of the peptide and the steroid.

Further studies on salt appetite following lateral hypothalamic lesions: effects of preoperative alimentary experiences.

Lateral hypothalamic lesions impair salt appetite, but rats with lesions show enhanced saline ingestion following natrorexigenic treatments if given preoperative salt drive experiences. In this study, the preoperative drive to ingest salt (without the consummatory experience of saline ingestion) was found to be necessary for this effect. Exposure to saline, or the treatments of water deprivation or insulin-induced feeding, when given preoperatively were not protective.

Recovery of salt appetite after lateral hypothalamic lesions: effects of preoperative salt drive and salt intake experiences.

This study presents further observations on the effects of preoperative salt experiences on salt appetite following lesions of the lateral hypothalamus. The results confirmed earlier findings that preoperative salt experiences can protect the rat against the usual deficit in regulatory salt intake that follows such lesions. However, the results suggested that there may be no specific feature of the preoperative salt experience that is critical for the protective effect since both salt drive experience without concomitant salt intake experience and salt intake experience without concomitant salt drive experience were effective.

Infusion of the serotonin1B (5-HT1B) agonist CP-93,129 into the parabrachial nucleus potently and selectively reduces food intake in rats.

Unilateral infusion of the selective 5-HT1B agonist, CP-93,129 (3-(1,2,5,6-tetrahydropyrid-4-yl) pyrrolo[3,2-b]pyrid-5-one) into the parabrachial nucleus (PBN) of the pons reduced food consumption by rats. The hypophagia was dose-related (ED50 approximately 1 nmol) and associated with fewer observations of feeding and more periods of inactivity. Water intake, grooming and exploratory activity were unaffected. CP-93,129 also decreased food intake when injected into the hypothalamic paraventricular nucleus, but this action was 50-fold less potent than administration into the PBN. Autoradiography demonstrated 5-HT1B sites in the PBN; this binding was displaced by CP-93,129. The results implicate parabrachial 5-HT1B receptors in mediating serotonergic enhancement of satiation.

Solubilization of oxytocin receptors in porcine renal LLC-PK1 cell membranes.

The present studies were undertaken to better characterize the pharmacological properties of oxytocin receptors (OTRs) of the porcine kidney cell line, LLC-PK1, in their natural membranous environment and after solubilization. In intact membranes, binding of a selective radioligand was rapid, reversible, saturable, and of high affinity. High-affinity agonist binding was reduced by a GTP analogue, suggesting that these OTRs are associated with G-protein(s). After solubilization with the zwitterionic detergent CHAPSO, OTRs retained their high affinity for the radioligand and rank order potency for oxytocin analogues, and agonist binding remained biphasic and GTP sensitive.

Immunological analysis of angiotensin AT2 receptors in peripheral tissues of neonatal and adult rats.

The peptide hormone angiotensin II (Ang II) is an important regulator of cardiovascular and body fluid homeostasis. Circulating Ang II mediates its physiological actions by activating Ang II receptors in both the periphery and the brain. Previous studies have demonstrated that Ang II receptor expression is high in neonates and decreases to adult levels as the animal matures. A greater proportion of this decline is due to reduced expression of the Type 2 (AT2) receptor subtype. In order to further investigate the expression of this receptor subtype, AT2-directed antisera were utilized to determine the expression of AT2 receptors in both neonatal and adult rat peripheral tissues by immunoblot analysis. The pattern of AT2 receptor immunoreactivity was largely consistent with previous studies employing autoradiographic and radioligand binding assays in peripheral tissues. However, AT2 receptor immunoreactivity was not seen in the adrenal, despite earlier reports of AT2 receptor expression in this peripheral tissue. These immunohistochemical studies also suggested that AT2 receptors undergo tissue-specific post-translational processing during development. Collectively, these results identify immunoreactive AT2 receptor populations in neonatal and adult rat peripheral tissues and further strengthen the hypothesis of AT2 receptor heterogeneity.

Angiotensin II stabilizes a multimeric type 2 (AT2) receptor complex in murine neuroblastoma N1E-115 cells.

Previous work has demonstrated that crosslinking of [125I]AngII to CHAPS solubilized angiotensin Type 2 receptors (AT2) in N1E-115 neuroblastoma cells identifies two radiolabeled proteins of 110 and 66 kDa. Similarly, affinity purification of AT2 receptors using AngII yields two proteins of 110 and 66 kDa. In the present study, anti-AT2 receptor antisera were used to examine the relationship between these two proteins. Agonist treatment (AngII) of intact cells increased the 110 kDa band while decreasing the 66 kDa protein. In intact or solubilized membranes, the ratio of 110 kDa/66 kDa proteins was significantly higher in the presence of an agonist and substantially lower with the antagonist Sar1,Ile8-AngII, suggesting that AngII stabilizes a large 110 kDa multimeric complex that may include the 66 kDa protein. To directly examine this hypothesis, anti-AT2 antisera were further purified against either the 110 or 66 kDa proteins. Both purified antibodies displayed crossreactivity with the two proteins. Moreover, when harshly reduced and denatured, the 110 kDa protein released a prominent immunoreactive 66 kDa protein, as well as other smaller proteins. Collectively, these results suggest that the 110 kDa protein consists, in part, of the 66 kDa protein and, as such, that an AT2 receptor subtype may exist as a multimeric complex that is stabilized by agonist occupancy.

Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat.

The central actions of the peptide hormone angiotensin II (AngII) are importantly involved in body fluid homeostasis. Included amongst these actions is a potent dipsogenic response that has been implicated in the thirst that develops during many forms of extracellular dehydration. The use of highly selective receptor antagonists has revealed that the Type 1 (AT1), and not the Type 2 (AT2), AngII receptor subtype mediates this drinking response. More recently, antisense oligonucleotides specific for the AT1 receptor have been developed and after intracerebroventricular (i.c.v.) administration, they significantly reduce the dipsogenic response elicited by a similar injection of AngII. In the present study AT1 antisense oligonucleotides were used to further investigate their effect on experimentally induced thirst in the rat. In addition, immunohistochemical analysis of biotin-labeled oligonucleotides was performed in order to correlate the behavioral effects of the oligonucleotides with their distribution in the brain. The results demonstrated that the antidipsogenic effects of the oligonucleotides were dose and time-dependent and were limited to those thirst challenges that involve activation of the renin-angiotensin system. Collectively, these results demonstrate the efficacy and behavioral specificity of these oligonucleotides, as well as their utility in investigating the physiological role of cerebral AngII receptor subpopulations in various models of thirst.

Brain oxytocin receptor antagonism disinhibits sodium appetite in preweanling rats.

Previous studies have shown that preweanling rats do not express an endogenous sodium appetite until postnatal day 12. The present studies tested the hypothesis that prior to 12 days of age sodium appetite, induced by either central administration of angiotensin II (AngII) or adrenalectomy, is inhibited by endogenous oxytocin (OT). After 9- or 10-day old animals were given a central injection of either an OT receptor antagonist or vehicle, they were infused intraorally with 4% sodium chloride which the animals could either swallow or reject. Intake was measured as the increase from initial body weight. There was very little sodium consumption by vehicle-injected animals that received sham surgery or adrenalectomy; however, the OT receptor antagonist significantly elevated sodium consumption in adrenalectomized animals. The OT antagonist also potentiated sodium intake after AngII pretreatment. These results suggest that the neurochemical circuits necessary for the expression of sodium appetite are present and functional as early as postnatal day 9; however, until 12 days of age this behavior is suppressed by endogenous OT.

Blockade of central angiotensin II type 1 and type 2 receptors suppresses adrenalectomy-induced NaCl intake in rats.

Removal of the adrenal glands, the main site for the synthesis of aldosterone, produces an intake of sodium that is essential for survival. Using central blockade of angiotensin II (Ang II) receptors with SarIle Ang II, previous studies have shown that this intake depends on the stimulation of the brain angiotensin system. In the present study, using intracerebroventricular injection of specific antagonists of Ang II type 1 (AT1) or type 2 (AT2) receptors (losartan and PD 123319, respectively), we confirm that activation of brain angiotensin is essential for the expression of adrenalectomy-induced NaCl intake. Moreover, we show that (a) AT1 but not AT2 receptor blockade alone suppresses NaCl intake and (b) doses of AT1 and AT2 receptor antagonists that separately have no effect on NaCl intake, suppress the behavior when combined. It is proposed that AT1 receptors mediate the natriorexigenic effect of Ang II and that AT2 receptors have a permissive role on AT1 receptor stimulation.